千紅製藥(002550.SZ)發佈半年報 淨利潤升6.97%至1.75億元
格隆匯8月23日丨千紅製藥(002550.SZ)發佈2019年半年度報告,實現營業收入約8.43億元,同比增長24.92%;歸屬於上市公司股東的淨利潤約1.75億元,同比增長6.97%;歸屬於上市公司股東的扣除非經常性損益的淨利潤約1.17億元,同比增長10.84%;基本每股收益0.1381元。
原料藥事業部方面:報告期內,精準分析與把握肝素鈉原料藥的市場動態,深挖老市場,發掘新市場;同時繼續發揮產供銷聯動優勢,原料藥市場銷售規模進一步擴大,營業利潤不斷增加。
國內製劑銷售方面:繼續深入實施“一體兩翼”多元化銷售模式,並按照各品種市場規模、成熟程度,實現國內製劑銷售規模持續增加。
重點產品:報告期內,通過對各市場的優勢分析,人員架構,市場佈局進行優化調整,使各項產品包括胰激肽原酶製劑、肝素鈉注射液的市場影響力和品牌宣傳力持續增加,毛利貢獻率進一步提升;
潛力產品:報告期內,公司通過學術推廣、OTC推廣等方式,不斷提升“怡美”、依諾肝素、達肝素鈉的深入開發能力與覆蓋區域,實現品種快速上量,成為公司國內製劑銷售的有力增長點;
新產品:報告期內,積極做好肝素鈉封管注射液、那屈肝素鈣注射液、診斷試劑新品種的市場準入工作,並實現部分產品上市銷售。
報告期內,董事會通過每季度聽取新藥研發進展彙報形式加強對研發工作的督導,提高眾紅和英諾升康兩個研究院的研發規劃和產品立項研發項目管理能力,完善研發平台建設、項目申報管理機制,加快新產品研發速度。報告期內,兩大研發平台的新藥臨牀研究及臨牀前研究工作均順利開展,其中小分子藥物研發平台QHRD107項目已進入一期臨牀階段;QHRD110項目與上海美迪西合作,開展臨牀前研發及臨牀申報一體化工作;大分子研發平台的ZHB202、ZHB206項目均已完成臨牀前研究工作,正在進行臨牀申報工作,平台開展的其他新藥項目也均在順利推進過程中。
報告期內,董事會督導經理室加強對重大項目進行監管:公司承擔的常州市重點建設項目——千紅創新藥物產業化項目已完成土地平整等準備工作,主體建築正在建設過程中;持續跟進重大技改項目,促進提高產品質量、控制產品成本,實現精細化管理,有效完成預期目標,同時根據已完成項目的經驗,對改進生產工藝、提升產品收率水平等起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.